Pharma & Biotech VC & Investment News
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Today's issue
Refine Search
Pharmaceutical
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Biotechnology
EY today released its 35th annual Biotech Beyond Borders Report. This finds that the biopharma industry is currently at an inflection point – grappling with a unique environment of macroeconomic uncertainty and constrained access to capital, including high interest rates, inflation, shifting regulatory policies and tariff turmoil. 18 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
Philadelphia-based biotech Vivodyne has raised $40 million in series A funding to advance its fully robotic, AI-powered platform that tests drug candidates on lab-grown human tissues. 30 May 2025
Biotechnology
Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing. 30 May 2025
Biotechnology
US biotech Moderna has reported encouraging early-stage results from a trial of its experimental vaccine for avian influenza, just as a significant federal funding agreement was unexpectedly withdrawn. 29 May 2025
Pharmaceutical
US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting neurotherapies aimed at treating major depressive disorder, Alzheimer’s disease, and other central nervous system (CNS) conditions. 27 May 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced a debt financing agreement for up to $262.5 million from funds managed by Blue Owl Capital. 27 May 2025
Biotechnology
French biotech tart-up EG 427 has successfully closed a 27 million-euro ($28.4 million) Series B financing round co-led by Andera Partners and Bpifrance - as part of the InnoBio investment strategy. 21 February 2025
Biotechnology
Boston, USA-based biotech Bambusa Therapeutics, which is developing bispecific antibodies for immunological and inflammatory (I&I) disorders, as announced the successful completion of its oversubscribed Series A financing of approximately $90 million. 17 February 2025
Biotechnology
Jena-based German biotech InflaRx has announced the pricing of an underwritten public offering, raising approximately $30 million. Guggenheim Securities is acting as the book-running manager. 14 February 2025
Biotechnology
Swiss biotech Oculis Holding yesterday announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, 0.01 francs nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses. 14 February 2025
Pharmaceutical
Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, has announced its emergence and the closing of an oversubscribed $93.5 million Series A financing. 13 February 2025
Pharmaceutical
France-based ophthalmics company PulseSight Therapeutics today announced the first close of its Series A financing with existing investor Pureos BioVentures committing new funds to support the Phase I study of PST-611 and enable preparation for a Phase IIa clinical trial. 13 February 2025
Biotechnology
Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing. 12 February 2025
Biotechnology
Shanghai-based biotech firm Hexaell Biotech has secured 200 million renminbi ($31 million) in a series B+ funding round. The investment was led by Shanghai Biomedical Fund, with continued support from existing backer Longpan Investment and participation from Guanghua Wutong. 11 February 2025
Biotechnology
Alumis and Acelyrin have agreed to merge in an all-stock deal, creating a late-stage biopharmaceutical company focused on immune-mediated diseases. 7 February 2025
Biotechnology
The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment by a long stretch. That honor belonged to the whopping $410 million netted by UK obesity group Verdiva Bio, but what Orbis’s VC round does show is the growing interest in macrocyclics as a drug class. 6 February 2025
Biotechnology
Omega Therapeutics has entered into a restructuring support agreement with Pioneering Medicines, an affiliate of its founding investor Flagship Pioneering. 5 February 2025
Pharmaceutical
AdvanCell announced the successful completion of an oversubscribed $112 million (US) Series C financing, making it the only Australian radiopharma company that has cash to burn. 4 February 2025
Biotechnology
German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate the development of its novel RNA-guided precision medicines. 4 February 2025
Pharmaceutical
Sionna Therapeutics hopes to raise $150 million and secure a market capitalization of about $692 million in an initial public offering (IPO). 4 February 2025
Biotechnology
Chinese biotech company Vigonvita Life Sciences has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, as the city continues to attract biotech listings. 3 February 2025
Biotechnology
Blackstone, the world’s largest alternative asset manager, is expanding its presence in the life sciences sector with a new multibillion-dollar fund dedicated to drug development. 31 January 2025
Pharmaceutical
San Francsiscan liver specialist 89bio has secured $250 million through a public stock offering, following a surge in its share price linked to recent trial data from a competitor. 29 January 2025
Biotechnology
Biopharma start-up Helicore Biopharma has emerged from stealth, with $65 million from a series A round co-led by Versant Ventures and OrbiMed. 29 January 2025
Biotechnology
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. 28 January 2025
Biotechnology
Boston, USA-based RNA focused biotech Atalanta Therapeutics today announced the completion of a $97 million Series B financing to support Phase I clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease. 28 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze